Table 4.
Univariable and multivariable analysis of overall survival in all patients (n = 102).
| Variable | Categorization | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95%CI) | P-value | Hazard ratio (95%CI) | P-value | ||
| Treatment | pembrolizumab vs. bevacizumab | 1.193 (0.464-3.070) | 0.714 | ||
| Age | ≥65 vs. <65 years | 1.265 (0.953-2.380) | 0.079 | 1.222 (0.395-3.779) | 0.728 |
| Sex | male vs. female | 0.905 (0.325-2.519) | 0.848 | ||
| Smoking history | yes vs. no | 1.242 (0.507-3.044) | 0.636 | ||
| ECOG | 1 vs. 0 | 0.960 (0.350-2.634) | 0.937 | ||
| Tumor histology | others vs. adenocarcinoma | 4.073 (0.523-31.370) | 0.180 | ||
| Stage | IV vs. III | 3.142 (0.419-23.550) | 0.265 | ||
| Bone metastases | yes vs. no | 5.361 (1.998-14.381) | 0.001 | 4.107 (1.434-11.761) | 0.009 |
| Brain metastases | yes vs. no | 1.433 (0.464-4.424) | 0.531 | ||
| Liver metastases | yes vs. no | 0.043 (0.001-68.446) | 0.404 | ||
| Chest metastases | yes vs. no | 1.913 (0.557-6.575) | 0.303 | ||
| Adrenal gland metastases | yes vs. no | 1.376 (0.455-4.160) | 0.572 | ||
| LDH | >300 vs. ≤300 U/L | 5.871 (2.165-15.925) | 0.001 | 4.300 (1.206-15.330) | 0.025 |
| NLR | >4.52vs. ≤4.52 | 4.134 (1.652-10.349) | 0.002 | 1.626 (0.376-7.030) | 0.516 |
| dNLR | >2.70 vs. ≤2.70 | 2.238 (0.841-5.956) | 0.107 | 0.359 (0.085-1.523) | 0.165 |
| PLR | >118.34 vs. ≤118.34 | 1.941 (0.700-5.382) | 0.203 | ||
| LMR | >1.95 vs. ≤1.95 | 0.120 (0.044-0.326) | <0.001 | 0.189 (0.068-0.523) | 0.039 |
| AEC | >0.19 vs. ≤0.19 × 109/L | 0.701 (0.416-1.180) | 0.181 | ||
| Radiotherapy combination | yes vs. no | 0.921 (0.496-1.710_ | 0.794 | ||
ECOG PS, Eastern Cooperative Oncology Group performance-status; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; AEC, absolute eosinophil count. Statistically significant values are bolded.